Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Phase I clinical trial shows drug shrinks melanoma brain metastases

18.05.2012
3-pronged study reveals high response rate in other advanced melanoma patients and activity in multiple cancers

An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet.

The drug dabrafenib, which targets the Val600 BRAF mutation that is active in half of melanoma cases, also cut the size of tumors in 25 of 36 patients with late-stage melanoma that had not spread to the brain. The drug also showed activity in other cancer types with the BRAF mutation.

"Nine out of 10 responses among patients with brain metastases is really exciting. No other systemic therapy has ever demonstrated this much activity against melanoma brain metastases," said study co-lead author Gerald Falchook, M.D., assistant professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Melanoma patients whose disease has spread to their brains have a median overall survival of four or five months, the researchers noted. Drugs used to treat brain metastases have response rates of 10 percent or lower. Surgery and stereotactic or whole-brain radiation also are used.

Tumor shrinkage in the nine responders ranged from 20 percent to 100 percent. In four cases, the brain metastases disappeared.

Drug's reach into brain a surprise

These results will need to be validated in additional clinical trials with larger groups of patients, Falchook said. "This changes how we think of this drug and exclusion criteria for future trials."

"Most clinical trials exclude patients with brain metastases because the drugs are assumed not to cross the blood-brain barrier," Falchook said. "These are the patients most in need of a clinical trial because their treatment options are so limited."

Dabrafenib, made by GlaxoSmithKline, was not designed to cross the blood-brain barrier, which protects the brain from toxic substances in the blood.

The drug's activity against brain metastases was initially a serendipitous finding at one study site. In one patient, a research PET scan performed just before starting dabrafenib revealed a brain metastasis, but this result was not available until after treatment began. The institution's ethics board approved the patient to continue treatment because a follow-up PET scan two weeks later showed decreased metabolic activity in the brain metastasis and subsequent MRIs showed a reduction in its size.

The team then designed a sub-study for 10 patients with untreated brain metastases, Falchook said. The mechanism by which dabrafenib reaches tumors in the brain is under investigation.

"In all of these patients with melanoma brain metastases, the tumors eventually progressed," Falchook said. Prevention of drug resistance remains a challenge in advanced cancers.

High response rate for those without brain metastases

184 patients enrolled at eight sites in the United States and Australia. Of these, 156 patients had melanoma that had spread to other organs. MD Anderson enrolled 64 patients.

The main purpose of a phase I clinical trial is to gradually escalate an experimental drug's dosage to evaluate side effects and establish the highest possible dose that can be safely given.

The researchers never reached a maximum-tolerated dose limit. No patients had to discontinue the drug due to side effects, and few patients experienced severe toxicity. "This is a very non-toxic drug, which is common with these newer, targeted therapies," Falchook said.

Based on response rates and the drug's pharmacokinetics – how the body metabolizes it – the team recommended an oral dose of 150 mg twice daily for future phase II and phase III trials. In the second stage of the phase I trial, they tested that dose in:

36 patients with melanoma with the Val600 BRAF mutation without brain metastases,

10 patients with untreated melanoma brain metastases, and

28 patients with other BRAF-mutant cancers.
Among the 36 melanoma patients without untreated brain metastases:
25 (69 percent) had a partial or complete response, which is shrinkage of at least 30 percent as determined by measuring tumor shrinkage with radiographic imaging,

18 (50 percent) had a confirmed response, meaning the reduction in size was observed in a second imaging scan at least one month later,

17 (47 percent) stayed on the trial for more than six months, and

Responses were seen in the less common Val600Lys BRAF mutation.
The confirmed response rate was similar to that in a phase III study of vemurafenib, the first drug approved for treatment of BRAF-mutant melanoma.

Among those with other types of cancers, patients with papillary thyroid, non-small cell lung and colorectal cancers had partial responses.

"This is further evidence that a tumor's molecular profile is as important, and possibly more important, than the organ where the cancer begins," Falchook said.

"We need to screen for BRAF and other molecular abnormalities in our patients' tumors," he said. "In many other tumor types BRAF mutations occur in small percentages of patients. If we're not testing for it routinely, these patients might never be treated with a promising targeted agent for their cancer."

Falchook has six melanoma patients still receiving dabrafenib, including five who are in complete remission. In addition, Falchook is still treating six papillary thyroid patients and one colorectal cancer patient whose tumors have not progressed on the treatment.

GlaxoSmithKline sponsored and funded the clinical trial. Phase II and phase III trials of dabrafenib for melanoma are under way.

Co-authors with Falchook are Razelle Kurzrock, M.D., of MD Anderson's Department of Investigational Cancer Therapeutics, and Kevin Kim, M.D. of MD Anderson's Department of Melanoma Medical Oncology; co-lead author Georgina Long, M.D., Ph.D., and senior author Richard Kefford, M.D., Ph.D., of Melanoma Institute Australia, Westmead Institute for Cancer Research and Westmead Hospital, University of Sydney, in Sydney, Australia; Tobias Arkenau, M.D., Ph.D., Prince of Wales Hospital, Randwick, Australia; Michael Brown, M.D., Ph.D., Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia; Omid Hamid, M.D., and Steven O'Day, M.D., of The Angeles Clinic and Research Institute. Los Angeles, Calif.; Jeffrey Infante, M.D., Sarah Cannon Research Institute, Nashville, Tenn.; Michael Millward, M.D., Cancer Council of Western Australia, Sir Charles Gairdner Hospital and University of Western Australia, Perth, Australia; Anna Pavlick, M.D., New York University School of Medicine; and Samuel Blackman, M.D., Ph.D., C. Martin Curtis, Peter Lebowitz, M.D., Ph.D., Bo Ma, Ph.D., and Daniele Ouellet, Ph.D., of GlaxoSmithKline Research and Development, Philadelphia.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Studies and Analyses:

nachricht Real-time feedback helps save energy and water
08.02.2017 | Otto-Friedrich-Universität Bamberg

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>